| Title: |
Molnupiravir: Mechanism of action, clinical, and translational science. |
| Authors: |
Maas, Brian M.1 (AUTHOR) brian.maas@merck.com, Strizki, Julie1 (AUTHOR), Miller, Randy R.1 (AUTHOR), Kumar, Sushma1 (AUTHOR), Brown, Michelle1 (AUTHOR), Johnson, Matthew G.1 (AUTHOR), Cheng, Mickie1 (AUTHOR), De Anda, Carisa1 (AUTHOR), Rizk, Matthew L.1 (AUTHOR), Stone, Julie A.1 (AUTHOR) |
| Source: |
CTS: Clinical & Translational Science. Feb2024, Vol. 17 Issue 2, p1-8. 8p. |
| Subject Terms: |
*MOLNUPIRAVIR, *COVID-19, *RNA replicase, *VIRAL load, *VIRAL replication, *VIRAL genomes |
| Abstract: |
Molnupiravir is an oral prodrug of the broadly active, antiviral ribonucleoside analog N‐hydroxycytidine (NHC). The primary circulating metabolite NHC is taken up into cells and phosphorylated to NHC‐triphosphate (NHC‐TP). NHC‐TP serves as a competitive substrate for viral RNA‐dependent RNA polymerase (RdRp), which results in an accumulation of errors in the viral genome, rendering virus replication incompetent. Molnupiravir has demonstrated activity against SARS‐CoV‐2 both clinically and preclinically and has a high barrier to development of viral resistance. Little to no molnupiravir is observed in plasma due to rapid hydrolysis to NHC. Maximum concentrations of NHC are reached at 1.5 h following administration in a fasted state. The effective half‐life of NHC is 3.3 h, reflecting minimal accumulation in the plasma following twice‐daily (Q12H) dosing. The terminal half‐life of NHC is 20.6 h. NHC‐TP exhibits a flatter profile with a lower peak‐to‐trough ratio compared with NHC, which supports Q12H dosing. Renal and hepatic pathways are not major routes of elimination, as NHC is primarily cleared by metabolism to uridine and cytidine, which then mix with the endogenous nucleotide pools. In a phase III study of nonhospitalized patients with COVID‐19 (MOVe‐OUT), 5 days of treatment with 800 mg molnupiravir Q12H significantly reduced the incidence of hospitalization or death compared with placebo. Patients treated with molnupiravir also had a greater reduction in SARS‐CoV‐2 viral load and improved clinical outcomes, compared with those receiving placebo. The clinical effectiveness of molnupiravir has been further demonstrated in several real‐world evidence studies. Molnupiravir is currently authorized or approved in more than 25 countries. [ABSTRACT FROM AUTHOR] |
|
Copyright of CTS: Clinical & Translational Science is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
